Valion Bio enters Initial Closing for $1.5M Series B Preferred shares
Valion Bio reached an Initial Closing for 1,500 Series B Preferred shares following an agreement with investor 3i, LP. The closing is contingent on CEO Michael Handley's resignation.
View filing at SEC.gov →